Recent Updates
Recently added Catalysts

CTT1057

Phase 3

Prostatic Neoplasms | Small molecule | Oncology |Novartis AG|Last Updated: Oct 20, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials2
Total Enrollment385

FDA Designations

No designations recorded

Clinical trial landscape

CTT1057 · 2 trials · 3 indications

Phase 3 1Phase 2 1
NCT04838613Study of Diagnostic Performance of [18F]CTT1057 in BCRProstatic Neoplasms
COMPLETED190 Analytics
PHASE3COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 in BCR
Prostatic NeoplasmsUnlock trial analytics

Study Endpoints

Primary Endpoints

Region-level Correct Localization Rate (CLR) of Vidoflufolastat (18F)
vidoflufolastat (18F) PET imaging acquired at Day 1 or Day 15 assessed against Composite Truth Standard (CTS) obtained within 8 weeks (before or after) of 18F-CTT PET scan or during follow-up (up to 90 days after radiotherapy for PSA level assessment)

Region-level correct localization rate (CLR) is defined as the percentage of regions containing at least one True Positive (TP) lesion (exactly localized correspondence between PET imaging and the reference standard), regardless of any co-existent False Positive (FP) findings within the same region, out of all regions containing at least one PET-positive finding.

Patient-level Positive Predictive Value (PPV) (With Anatomical Localization) of Vidoflufolastat (18F)
vidoflufolastat (18F) PET imaging acquired at Day 1 or Day 15 assessed against Composite Truth Standard (CTS) obtained within 8 weeks (before or after) of 18F-CTT PET scan or during follow-up (up to 90 days after radiotherapy for PSA level assessment)

Patient-level positive predictive value (PPV) is defined as the percentage of participants who have at least one True Positive (TP) lesion (exactly localized correspondence between PET imaging and the reference standard), regardless of any co-existent False Positive (FP) findings, out of all participants who are PET/CT scan positive.

Patient-level Sensitivity of Vidoflufolastat (18F) - % Sensitivity
vidoflufolastat (18F)7 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from vidoflufolastat (18F) scan

Sensitivity of vidoflufolastat (18F) Positron Emission Tomography (PET) imaging, considering Prostate Specific Membrane Antigen (PSMA) positive patients as those who show at least one pathological vidoflufolastat (18F) uptake either in the primary tumor and/or metastatic Pelvic Lymph Node (PLN) regions, with anatomically localized correspondence with the Standard of Truth (SoT).

Region-level Specificity of Vidoflufolastat (18F) - % Specificity
vidoflufolastat (18F) PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from vidoflufolastat (18F) scan

Specificity of vidoflufolastat (18F) PET imaging, defined as proportion of PLN regions that test negative for lymph nodes on vidoflufolastat (18F) among those that are lymph node negative on the SoT.

Secondary Endpoints

Patient-level Sensitivity of Vidoflufolastat (18F)
vidoflufolastat (18F) PET imaging acquired at Day 1 or Day 15 assessed against Composite Truth Standard (CTS) obtained within 8 weeks (before or after) of 18F-CTT PET scan or during follow-up (up to 90 days after radiotherapy for PSA level assessment)
Patient-level Specificity of Vidoflufolastat (18F)
vidoflufolastat (18F) PET imaging acquired at Day 1 or Day 15 assessed against Composite Truth Standard (CTS) obtained within 8 weeks (before or after) of 18F-CTT PET scan or during follow-up (up to 90 days after radiotherapy for PSA level assessment)
Patient-level Negative Predictive Value (NPV) of Vidoflufolastat (18F)
vidoflufolastat (18F) PET imaging acquired at Day 1 or Day 15 assessed against Composite Truth Standard (CTS) obtained within 8 weeks (before or after) of 18F-CTT PET scan or during follow-up (up to 90 days after radiotherapy for PSA level assessment)
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
PET/CT imaging with [18F]CTT1057 followed by [68Ga]Ga-PSMA-11 or vice versaEXPERIMENTALAll eligible participants were assigned to one of the following two PET/CT scan sequences at random in a 1:1 ratio: * Sequence 1: \[18F\]CTT1057 on Day 1 (investigational imaging agent of interest) followed by \[68Ga\]Ga-PSMA-11 at least 14 days apart (as part of CTS if required, and for secondary endpoint) * Sequence 2: \[68Ga\]Ga-PSMA-11 (as part of CTS if required, and for secondary endpoint) on Day 1 followed by \[18F\]CTT1057 (investigational imaging agent of interest) at least 14 days apart
PET/CT imaging with [18F]CTT1057EXPERIMENTALAll eligible participants will be enrolled to receive \[18F\]CTT1057 imaging agent on Day 1 and have PET/CT scan

Interventions

NameTypeDescription
[18F]CTT1057DRUGSingle intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
[68Ga]Ga-PSMA-11DRUGSingle intravenous dose of approximately 150 MBq and subsequent PET/CT scan
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 100 Years
SexMALE
Healthy VolunteersNo
Study Sites13

Inclusion Criteria * Signed informed consent must be obtained prior to participation in the study * Biopsy proven prostate adenocarcinoma. * Biochemical recurrence following initial definitive therapy (with either RP or curative intent radiation therapy) as defined: by AUA criteria (Cookson et al ...

Countries:United StatesFranceSpainSwitzerlandItaly
Unlock Eligibility Criteria

Frequently asked questions about CTT1057

What is CTT1057 used for in prostatic neoplasms?

CTT1057 is an investigational small molecule being studied for use in prostatic neoplasms, specifically prostate cancer. It is a diagnostic imaging agent, as it is being evaluated in clinical trials for its diagnostic performance in detecting prostate cancer recurrence and PSMA-positive tumors. It is not approved and remains in clinical development.

Who makes CTT1057?

CTT1057 is being developed by Novartis AG, which trades on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the diagnostic performance of this investigational imaging agent in prostate cancer patients.

What phase is CTT1057 in?

CTT1057 is in Phase 3 clinical development. One completed Phase 3 trial evaluated its diagnostic performance in biochemical recurrence of prostate cancer, and a completed Phase 2 trial assessed its ability to detect PSMA-positive tumors. It remains investigational and is not FDA approved.

What clinical trials is CTT1057 in?

CTT1057 has been studied in two completed clinical trials. NCT04838613 was a Phase 3 study of its diagnostic performance in biochemical recurrence of prostate cancer with 190 participants. NCT04838626 was a Phase 2 study for PSMA-positive tumor detection with 195 participants. Both enrolled adult males.

How does CTT1057 work?

CTT1057 is a small molecule diagnostic imaging agent that targets prostate-specific membrane antigen, or PSMA, which is overexpressed on prostate cancer cells. By binding to PSMA, it enables detection of prostate cancer lesions through imaging. It is being studied for its diagnostic performance in prostate cancer.